Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Hypertension. 2010 Nov 15;57(1):94–102. doi: 10.1161/HYPERTENSIONAHA.110.160242

Figure 3. Ad-VEGF therapy rescues the angiogenic potential of BPH/5 serum as measured in an endothelial tube formation assay.

Figure 3

A) Representative images of individual wells of HUVEC cells treated with serum collected from e12.5 C57 and BPH/5 that had undergone tail vein injections of Ad-LacZ or Ad-VEGF on e7.5. White bar (upper right) indicates a representative measurement of tube length. B) Summary of tube lengths normalized to 5% FBS in cells treated with serum from non-pregnant (NP) mice or from e12.5 C57 and BPH/5 mice given no treatment (none) or administered Ad-LacZ or Ad-VEGF on e7.5. NP: n=8 per strain; no treatment and Ad-LacZ: n=5-8 per group and strain; Ad-VEGF: n=5-12 per group and strain. *p<0.05 vs NP matched strain; † p<0.05 vs. C57 in matched treatment; # p<0.05 vs BPH/5 none or Ad-LacZ.